Incannex Healthcare Inc
IXHL0.458USD
+0.072+18.78%
Market hours （ET）Quotes delayed by 15 min
8.14MMarket Cap
LossP/E TTM
More Details of Incannex Healthcare Inc Company
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Company Info
Ticker SymbolIXHL
Company nameIncannex Healthcare Inc
IPO dateMar 18, 2022
CEOMr. Joel Latham
Number of employees9
Security typeOrdinary Share
Fiscal year-endMar 18
Address8 Century Circuit
City
Stock exchangeNASDAQ Capital Market Consolidated
CountryAustralia
Postal code2153
Phone61409840786
Website
Ticker SymbolIXHL
IPO dateMar 18, 2022
CEOMr. Joel Latham
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.24M
-21.24%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
744.72K
-3.25%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
245.85K
-9.23%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
17.93K
-89.40%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Luigi M. (Lou) Barbato, M.D.
Dr. Luigi M. (Lou) Barbato, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert B. Clark
Mr. Robert B. Clark
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.24M
-21.24%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
744.72K
-3.25%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
245.85K
-9.23%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
17.93K
-89.40%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
Australia
74.00K
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 16
Updated: Wed, Jul 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Great Point Capital LLC
6.55%
L1 Capital Global Opportunities Master Fund Ltd.
6.55%
S.H.N. Financial Investments Ltd
6.55%
Latham (Joel)
4.22%
Valentine (Troy Robert)
2.95%
Other
73.17%
Shareholders
Shareholders
Proportion
Great Point Capital LLC
6.55%
L1 Capital Global Opportunities Master Fund Ltd.
6.55%
S.H.N. Financial Investments Ltd
6.55%
Latham (Joel)
4.22%
Valentine (Troy Robert)
2.95%
Other
73.17%
Shareholder Types
Shareholders
Proportion
Corporation
13.11%
Individual Investor
13.03%
Investment Advisor
8.09%
Hedge Fund
0.35%
Research Firm
0.18%
Investment Advisor/Hedge Fund
0.03%
Other
65.22%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
39
10.24M
34.78%
+3.35M
2025Q1
36
6.86M
34.69%
+1.54M
2024Q4
34
5.22M
29.25%
-10.87K
2024Q3
35
5.23M
32.43%
+928.92K
2024Q2
32
5.32M
33.29%
+935.04K
2024Q1
33
4.38M
27.39%
+2.50M
2023Q4
26
4.32M
27.01%
+2.81M
2023Q3
13
32.37K
0.05%
-34.33K
2023Q2
11
12.21K
0.02%
-63.09K
2023Q1
10
20.53K
0.03%
-60.83K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Great Point Capital LLC
1.93M
6.55%
+1.93M
--
Apr 09, 2025
L1 Capital Global Opportunities Master Fund Ltd.
1.93M
6.55%
+460.27K
+31.34%
Apr 09, 2025
S.H.N. Financial Investments Ltd
1.93M
6.55%
+1.93M
--
Apr 09, 2025
Latham (Joel)
1.24M
4.22%
-335.00K
-21.24%
Apr 09, 2025
Valentine (Troy Robert)
869.01K
2.95%
-167.50K
-16.16%
Apr 09, 2025
Anastassov (George)
744.72K
2.53%
-25.00K
-3.25%
Apr 09, 2025
Changoer (Lekhram)
639.55K
2.17%
--
--
Apr 09, 2025
AdvisorShares Investments, LLC
295.03K
1%
+129.54K
+78.27%
Mar 31, 2025
Widdows (Peter)
245.85K
0.84%
-25.00K
-9.23%
Apr 09, 2025
Citadel Advisors LLC
102.87K
0.35%
+102.87K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AdvisorShares Psychedelics ETF
0.73%
Amplify Alternative Harvest ETF
0%
AdvisorShares Psychedelics ETF
Proportion0.73%
Amplify Alternative Harvest ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
